Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 12/20 | 0.41 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.31 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20358164 | 1.00 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL20358061 | 1.00 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL20358106 | 1.00 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL20358105 | 1.00 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18476619 | 1.00 | FOLH1 (0.41) | FOLH1NAALAD2RIMKLA | |
| SCHEMBL18451343 | 0.94 | FOLH1 (0.37) | FOLH1 | |
| SCHEMBL18476460 | 0.89 | FOLH1 (0.30) | FOLH1 | |
| SCHEMBL29746760 | 0.89 | FOLH1 (0.30) | FOLH1 | |
| SCHEMBL20370939 | 0.89 | FOLH1 (0.30) | FOLH1 | |
| SCHEMBL18476459 | 0.89 | FOLH1 (0.30) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240041900-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2024-02-08 | — | — | US | disclosed |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| US-11110104-B2 | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-09-07 | — | — | US | disclosed |
| US-20210145779-A1 | Methods for Cancer and Immunotherapy Using Prodrugs of Glutamine Analogs | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2021-05-20 | — | — | US | disclosed |
| US-10842763-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-11-24 | — | — | US | disclosed |
| US-10568868-B2 | Methods and compositions for treating metabolic reprogramming disorders | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190216757-A1 | Methods for Cancer and Immunotherapy Using Prodrugs of Glutamine Analogs | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-07-18 | — | — | US | disclosed |
| US-20180221337-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180221395-A1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING PRODRUGS OF GLUTAMINE ANALOGS | UNIV JOHNS HOPKINS (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180193362-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | FOLH1 1528/4885NAALAD2 319/4885RIMKLA 16/4885 |
| US-20190216757-A1 | Methods for Cancer and Immunotherapy Using Prodrugs of Glutamine Analogs | ADORA2A, ADORA1, ADORA2B | FOLH1 180/4885NAALAD2 1054/4885RIMKLA 1394/4885 |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | ADORA2A, ADORA1, ADORA2B | FOLH1 189/4885NAALAD2 1040/4885RIMKLA 1398/4885 |
| US-20180221337-A1 | METHODS AND COMPOSITIONS FOR TREATING METABOLIC REPROGRAMMING DISORDERS | GLS, GLS2, PC | FOLH1 1804/4885NAALAD2 1949/4885RIMKLA 332/4885 |
| US-10568868-B2 | Methods and compositions for treating metabolic reprogramming disorders | GLS, GLS2, PC | FOLH1 1804/4885NAALAD2 1949/4885RIMKLA 332/4885 |
| US-20210145779-A1 | Methods for Cancer and Immunotherapy Using Prodrugs of Glutamine Analogs | ADORA2A, ADORA1, ADORA2B | FOLH1 189/4885NAALAD2 1040/4885RIMKLA 1398/4885 |
| US-11110104-B2 | Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders | GLUL, GLS2, SLC1A2 | FOLH1 1528/4885NAALAD2 319/4885RIMKLA 16/4885 |
| US-20240041900-A1 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | GLUL, GLS2, SLC1A2 | FOLH1 1528/4885NAALAD2 319/4885RIMKLA 16/4885 |
| US-10842763-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | ADORA2A, ADORA1, ADORA2B | FOLH1 189/4885NAALAD2 1040/4885RIMKLA 1398/4885 |
| US-20180221395-A1 | METHODS FOR CANCER AND IMMUNOTHERAPY USING PRODRUGS OF GLUTAMINE ANALOGS | ADORA2A, ADORA1, ADORA2B | FOLH1 189/4885NAALAD2 1040/4885RIMKLA 1398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.